Murray J M, Coldman A J
School of Mathematics, University of New South Wales, Sydney, NSW 2052, Australia.
Math Biosci. 2003 Sep;185(1):73-87. doi: 10.1016/s0025-5564(03)00093-2.
Optimal drug regimens for cancer chemotherapy are determined when knowledge is only available on the behaviour of the tumour and the drugs used, over a population of patients. The case of two drugs is investigated where they are equivalent on average. Our calculations indicate that the optimal regimen has both drugs given initially but then sequences the two drugs. Our calculations also indicate that as tumour heterogeneity increases, the benefit to be gained from the optimal regimen can decrease in comparison to reasonable regimens. This has the effect of complicating the calculation of optimal regimens in a clinical setting, and may explain why results in experimental oncology fail to carry over to clinical oncology.
当仅了解肿瘤行为和所用药物在患者群体中的情况时，便可确定癌症化疗的最佳药物方案。研究了两种平均等效药物的情况。我们的计算表明，最佳方案是一开始同时给予两种药物，但随后对这两种药物进行排序。我们的计算还表明，随着肿瘤异质性增加，与合理方案相比，最佳方案所带来的益处可能会减少。这使得在临床环境中计算最佳方案变得复杂，并且可能解释了为什么实验肿瘤学的结果无法应用于临床肿瘤学。
